Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

The first GLP-1 receptor agonist approved for obesity was liraglutide, marketed in the U.S. as Saxenda, in 2014. However, the ...

The GLP-1 medications liraglutide and semaglutide, as well as the dual GLP-1 and glucose-independent insulinotropic ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

The updated AAP clinical guidelines on obesity treatment recommend offering the full spectrum of care upon initial obesity ...